TODDD™ Platform
Glaucoma
Key Facts
About Amorphex Therapeutics
Amorphex Therapeutics is an ophthalmic drug delivery company advancing its proprietary TODDD™ platform, a soft device worn under the eyelid for sustained, continuous drug release. The technology addresses critical shortcomings of topical eye drops, including poor patient adherence, inconsistent dosing, and side effects from preservatives. Founded by a team with a successful track record in ophthalmic product development, the company is currently in the preclinical stage, seeking clinical funding and strategic partnerships to advance its pipeline targeting glaucoma, retinal diseases, and myopia progression.
View full company profileAbout Amorphex Therapeutics
Amorphex Therapeutics is an ophthalmic drug delivery company advancing its proprietary TODDD™ platform, a soft device worn under the eyelid for sustained, continuous drug release. The technology addresses critical shortcomings of topical eye drops, including poor patient adherence, inconsistent dosing, and side effects from preservatives. Founded by a team with a successful track record in ophthalmic product development, the company is currently in the preclinical stage, seeking clinical funding and strategic partnerships to advance its pipeline targeting glaucoma, retinal diseases, and myopia progression.
View full company profileAbout Amorphex Therapeutics
Amorphex Therapeutics is an ophthalmic drug delivery company advancing its proprietary TODDD™ platform, a soft device worn under the eyelid for sustained, continuous drug release. The technology addresses critical shortcomings of topical eye drops, including poor patient adherence, inconsistent dosing, and side effects from preservatives. Founded by a team with a successful track record in ophthalmic product development, the company is currently in the preclinical stage, seeking clinical funding and strategic partnerships to advance its pipeline targeting glaucoma, retinal diseases, and myopia progression.
View full company profileTherapeutic Areas
Other Glaucoma Drugs
| Drug | Company | Phase |
|---|---|---|
| INM-088 | InMed Pharmaceuticals | Preclinical |
| ANX007 | Annexon Biosciences | Phase 2 |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| hOTX2 | BrainEver | Discovery |
| Glaucoma Treatment | BVI Medical | Commercial |
| MediPrint Lens (Glaucoma) | MediPrint Ophthalmics | Phase 2b |
| Glaucoma Program | Broadwing Bio | Pre-clinical |
| MSC Exosomal Eye Serum | Vitti Labs | Pre-clinical |
| BTQ1902 | Betaliq | Phase 2 |
| Glaucoma Diagnostics | Avellino Laboratories | Development/Accreditation |
| Glaucoma Portfolio | Visufarma | Commercial |
| DARC for Glaucoma | Novai | Exploratory Biomarker in Clinical Studies |